Download PDF
Pharmacopsychiatry 2006; 39(1): 30-34
DOI: 10.1055/s-2006-931479
Original Paper
© Georg Thieme Verlag KG Stuttgart · New York

Efficacy and Safety of Outpatient Alcohol Detoxification with a Combination of Tiapride/Carbamazepine: Additional Evidence

M. Soyka1 , F. Schmidt1 , 2 , P. Schmidt1
  • 1Psychiatric Hospital, University of Munich, Nussbaumstr. 7, 80336 Munich, Germany
  • 2Klientenzentrierte Problemberatung Dachau, Münchner Str. 33, 85221 Dachau, Germany
This study was supported by an unrestricted educational grant by the pharmaceutical company Sanofi-Aventis
Further Information

Publication History

Received: 18.7.2005 Revised: 13.9.2005

Accepted: 10.10.2005

Publication Date:
02 February 2006 (online)

Also available at
    Permissions and Reprints

Background: Few medications have been tested for outpatient alcohol detoxification. Previously we had shown a combination of carbamazepine and tiapride to be effective in an open study. This database is an extension of our previous work. Methods: This was an open prospective study to examine the efficacy, practicability and medical safety of a combination of tiapride and carbamazepine in outpatient detoxification of alcohol dependent patients. Patients were carefully screened for relevant neuropsychiatric disorders and then seen on a daily outpatient basis. Results: A total number of 116 consecutively admitted patients entered the programme; 107 (92 %) successfully ended the treatment. The mean initial dose for tiapride was 289 mg and for carbamazepine 502 mg. No serious medical complications or adverse events were observed except for one case of delirium tremens. Only four patients dropped out because of side effects. In general medication was well tolerated. Withdrawal symptomatology as indicated by CIWA-A-scores decreased over time. Conclusions: Results from this study give further evidence for a combination of tiapride and the anticonvulsant carbamazepine as an effective and safe treatment for outpatient alcohol detoxification in patients with moderate severity of withdrawal syndrome. Further randomized trials are warranted to examine the efficacy of this combination in outpatient alcohol withdrawal.

References

  • 1 Agricola R, Mazzarino M, Urani R. Treatment of acute alcohol withdrawal syndrome with carbamazepine: A double blind comparison with tiapride.  J Intern Med Res. 1982;  10 160-165
    PubMedGoogle Scholar
  • 2 Albani F, Riva R, Baruzzi A. Carbamazepine clinical pharmacology: a review.  Pharmacopsychiatry. 1995;  28 235-244
    PubMedGoogle Scholar
  • 3 Allain H, Dauzenberg P H, Maurer K, Schuck S, Bonhomme D, Gerard D. Double blind study of tiapride versus haloperidol and placebo agitation and aggressiveness in elderly patients with cognitive impairment.  Psychopharmacology. 2000;  148 361-366
    CrossrefPubMedGoogle Scholar
  • 4 Alterman A I, Bedrick J, Cacciola J S. et al . Personality pathology and drinking in young men at high and low familail risk for alcoholism.  J Stud Alcohol. 1998;  59 495-502
    PubMedGoogle Scholar
  • 5 Bjorkquist S E, Isohanni M, Makela R. et al . Ambulant treatment of alcohol withdrawal symptoms with carbamazepine: a formal multicentre double-blind comparison with placebo.  Acta Psychiatr Scand. 1976;  53 333-342
    PubMedGoogle Scholar
  • 6 Blundell R D. Ambulatory Detoxification of patients with Alcohol Dependence.  Am Fam Physician. 2005;  71 495-502
    PubMedGoogle Scholar
  • 7 Bonnet U, Ranger M, Leweke F M, Maschie M, Kowalski T, Gastpar M. Treatment of Alcohol Withdrawal Syndrome with Gabapentin.  Pharmacopsychiatry. 1999;  32 107-109
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Collins M N, Burns T, Van den Berk P AH, Tubman G F. A structured Programme for Out-patient Alcohol Detoxification.  Br J Psychiatry. 1990;  56 871-874
    PubMedGoogle Scholar
  • 9 Croissant B, Scherle T, Diehl A, Heinz A, Mann K. Oxcarbazepine in Alcohol Relapse Prevention.  Pharmacopsychiatry. 2004;  37 306-307
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Feldman D J, Pattison E M, Sobell L C. et al . Out-Patient alcohol detoxification: initial findings on 564 patients.  Am J Psychiatry. 1975;  132 407-412
    PubMedGoogle Scholar
  • 11 Flygenring J, Hansen J, Holst B, Petersen E, Sorensen A. Treatment of alcohol withdrawal symptoms in hospitalized patients. A randomized, double-blind comparison of carbamazepine (Tegretol) and barbital (Diemal).  Acta Psychiatr Scand. 1984;  69 398-408
    PubMedGoogle Scholar
  • 12 Franz M, Dlabal H, Kunz S, Ulferts J, Gruppe H, Gallhofer B. Treatment of alcohol withdrawal: tiapride and carbamazepine versus clomethiazole. A pilot study.  Eur Arch Psychiatry Clin Neurosci. 2001;  251 185-192
    CrossrefPubMedGoogle Scholar
  • 13 Gartenmeier A, Pelzer E, Soyka M. Treatment of alcohol withdrawal syndrome with combined carbamazepine and tiapride in a patient with probable sleep apnoea syndrome.  Pharmacopsychiatry. 2005;  3 96-98
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Gottesleben A, Willemsen D, Wolf C. Retardiertes Carbamazepin in der Therapie des alkoholischen Prädelirs.  Akt Neurol. 1995;  22 60-65
    PubMedGoogle Scholar
  • 15 Hayashida M, Alterman A I, McLellan T. et al . Comparative effectiveness and costs of inpatient and outpatient detoxification of patients with mild-to-moderate alcohol withdrawal syndrome.  N Engl J Med. 1989;  320 358-365
    PubMedGoogle Scholar
  • 16 Johnson B A. An overview of the development of medications including novel anticonvulsants for the treatment of alcohol dependence.  Expert Opin Pharmacotherapy. 2004;  5 1943-1955
    PubMedGoogle Scholar
  • 17 Johnson B A, Ait-Daoud N, Bowden C L, DiClemente C C, Roache J D, Lawson K, Javors M A, Ma J Z. Oral topiramate for treatment of alcohol dependence: a randomized controlled trial.  Lancet. 2003;  361 1677-1685
    CrossrefPubMedGoogle Scholar
  • 18 Jonasch K, Mende M. Treatment of Alcohol Withdrawal with Tiapride (TiapridexR) vs. Clomethiazol (DistraneurinR). An Open-Label trial (in German).  Krankenhauspsychiatrie. 2004;  15 114-116
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Lepola U, Kokko S, Nuutila J, Gordin A. Tiapride and chlordiazepoxide in acute alcohol withdrawal. A controlled clinical trial.  International J Clin Pharm Res. 1984;  5 321-326
    PubMedGoogle Scholar
  • 20 Lucht M J, Kuehn K U, Schroeder W, Armbruster J, Abraham G, Schattenberg A, Gaensicke M, Barnow S, Tretzel H, Herrmann F H, Freyberger H J. Influence of the dopamine D2 receptor (DRD2) exon 8 genotype on efficacy of tiapride and clinical outcome of alcohol withdrawal.  Pharmacogenetics. 2001;  11 647-653
    CrossrefPubMedGoogle Scholar
  • 21 Lucht M, Kuehn K U, Armbruster J, Abraham G, Gaensicke M, Barnow S, Tretzel H, Freyberger H J. Alcohol withdrawal Treatment in intoxicated Vs Non-Intoxicated patients: A controlled open-label Study with Tiapride/Carbamazepine, Clomethiazole and Diazepam.  Alcohol Alcohol. 2003;  38 168-175
    PubMedGoogle Scholar
  • 22 Majumdar S K. Chlomethiazole: Current status in the treatment of the acute ethanol withdrawal syndrome.  Drug Alcohol Depend. 1990;  27 201-207
    PubMedGoogle Scholar
  • 23 Malcolm R, Myrick H, Brady K T, Ballenger J C. Update on anticonvulsants for the treatment of alcohol withdrawal.  Am J Addict. 2001;  10 (Suppl.) 16-23
    PubMedGoogle Scholar
  • 24 Malcolm R, Myrick H, Roberts J, Wang W, Anton R F, Ballenger J C. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial.  J Gen Intern Med. 2002;  17 349-355
    CrossrefPubMedGoogle Scholar
  • 25 Malcolm R, Ballenger J C, Sturgis E T, Anton R A. Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal.  Am J Psychiatry. 1989;  146 617-621
    PubMedGoogle Scholar
  • 26 Mariani J J, Levin F R. Pharmacotherapy for Alcohol-Related Disorders: What Clinicians Should Know.  Harv Rev Psychiatry. 2004;  23 351-366
    PubMedGoogle Scholar
  • 27 Mayo-Smith MF for the American Society of Addiction M edicine, Working Group on Pharmacological Management of Alcohol W ithdrawal. Pharmacological Management of Alcohol Withdrawal. A Meta-analysis and Evidence-Based Practice Guideline.  JAMA. 1997;  278 144-151
    Google Scholar
  • 28 Mayo-Smith M F, Beecher L H, Fischer T L, Gorekick D A, Guillaume J L, Hill A, Jara G, Kasser C, Melbourne J. Management of Alcohol Withdrawal Delirium. An Evidence-Based Guideline.  Arch Intern Med. 2004;  164 1405-1412
    CrossrefPubMedGoogle Scholar
  • 29 Mueller T I, Stout R L, Rudden S, Brown R A, Gordon A, Dolomon D A, Recupero P R. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence.  Alcohol Clin Exp Res. 1997;  21 86-92
    CrossrefPubMedGoogle Scholar
  • 30 Murphy D J, Shaw G K, Clarke I. Tiapride and chlormethiazole in alcohol withdrawal: a double-blind trial.  Alcohol Alcohol. 1983;  18 227-237
    PubMedGoogle Scholar
  • 31 O’Connor P G, Gottlieb L D, Kraus M L, Segal S R, Horwitz R I. Social and clinical features as predictors of outcome in outpatient alcohol withdrawal.  J Gen Intern Med. 1991;  6 312-316
    PubMedGoogle Scholar
  • 32 Palsson A. The efficacy of early chlormethiazole medication in the prevention of delirium tremens. A retrospective study of the outcome of different drug treatment strategies at the Helsingborg psychiatric clinics, 1975-1980.  Acta Psychiatr Scand. 1986;  73 (Suppl. 329) 140-145
    PubMedGoogle Scholar
  • 33 Peters D H, Faulds D. Tiapride. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome.  Drugs. 1994;  47 1010-1032
    CrossrefPubMedGoogle Scholar
  • 34 Ritola E, Malinen L. A double-blind comparison of carbamazepine and clomethiazole in the treatment of alcohol withdrawal syndrome.  Acta Psychiatr Scand. 1981;  64 254-259
    CrossrefPubMedGoogle Scholar
  • 35 Robert P H, Allain H. Clinical management of agitation in the elderly with tiapride.  Eur Psychiatry. 2001;  16 42s-47
    CrossrefPubMedGoogle Scholar
  • 36 Rubio G, Ponce G, Jime’nez-Arriero M A, Palomo T, Manzanares J, Ferre F. Effects of Topiramate in the Treatment of Alcohol Dependence.  Pharmacopsychiatry. 2004;  37 37-40
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Scatton B, Cohen C, Perrault G, Oblin A, Claustre Y, Schoemaker H, Sanger D J, Rouquier L, Porsolt R. The preclinical pharmacologic profile of tiapride.  Eur Psychiatry. 2001;  16 29s-34
    CrossrefPubMedGoogle Scholar
  • 38 Seifert J, Peters E, Kahn K, Metzner C, Ohlmeier M, Te Wildt B, Emrich H M, Schneider U. Treatment of alcohol withdrawal: chlormethiazole vs. carbamazepine and the effect on memory performance - a pilot study.  Addict Biol. 2004;  9 43-51
    CrossrefPubMedGoogle Scholar
  • 39 Shaw G K, Majumdar S K, Waller S, MacGarvie J, Dunn G. Tiapride in the long-term management of alcoholics of anxious or depressive treatment.  Br J Psychiatry. 1987;  150 164-168
    PubMedGoogle Scholar
  • 40 Shaw G K, Waller S, Majumdar S K, Alberts J L, Latham C J, Dunn G. Tiapride in the prevention of relapse in recently detoxified alcoholics.  Br J Psychiatry. 1994;  165 515-523
    PubMedGoogle Scholar
  • 41 Soyka M, Morhart-Klute V, Horak M. A combination of carbamazepine/tiapride in outpatient alcohol detoxification. Results from an open clinical study.  Eur Arch Psychiatry Clin Neurosci. 2002;  252 197-200
    CrossrefPubMedGoogle Scholar
  • 42 Soyka M, Horak M, Löhnert B, Löhnert E, Rüster P, Möller H J. Ambulante Entgiftung Alkoholabhängiger - Ein Modellversuch.  Nervenheilkunde. 1999;  8 147-152
    PubMedGoogle Scholar
  • 43 Soyka M, Clausius N, Hohendorf G, Horak M. Outpatient detxofication with carbamazepine and tiparide - medical safety and results of a follow-up study (in German).  Suchtmed. 2004;  6 307-311
    PubMedGoogle Scholar
  • 44 Stinnett J L. Outpatient detoxification of the alcoholic.  Int J Addict. 1982;  17 1031-1046
    PubMedGoogle Scholar
  • 45 Stockwell T, Bolt E, Hooper J. Detoxification from alcohol at home managed by general practitioners.  Br Med J. 1986;  292 733-735
    PubMedGoogle Scholar
  • 46 Stuppaeck C H, Barnas C, Hackenberg K, Miller C H, Fleischhacker W W. Carbamazepine monotherapy in the treatment of alcohol withdrawal.  Int Clin Psychopharmacol. 1990 ;  5 273-278
    PubMedGoogle Scholar
  • 47 Stuppaeck C H, Barnas C, Falk M, Guenther V, Hummer M, Oberbauer H, Pycha R, Whitworth A B, Fleischhacker W W. Assessment of the alcohol withdrawal syndrome-validity and reliability of the translated and modified clinical institute withdrawal assessment for alcohol scale (CIWA-A).  Addiction. 1994;  89 1287-1292
    PubMedGoogle Scholar
  • 48 Stuppaeck C, Pycha R, Miller C, Whitworth A, Oberbauer H, Fleischhacker W. Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study.  Alcohol Alcohol. 1992;  27 153-158
    PubMedGoogle Scholar
  • 49 Sullivan J T, Sykora K, Schneiderman J, Neranjo C A, Sellers E M. Assessment of alcohol withdrawal: the revised clinical institute withdrawal scale (CIWA-Ar).  Br J Addict. 1989;  84 1353-1357
    CrossrefPubMedGoogle Scholar
  • 50 Thome J, Wiesbeck G A, Vince G H. Carbamazepin in der Behandlung des Alkoholentzugssyndroms - Eine Übersicht zum aktuellen Forschungsstand.  Fortschr Neurol Psychiat. 1994;  62 125-133
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 Webb M, Unwin A. The outcome of outpatient withdrawal from alcohol.  Br J Addict. 1988;  83 929-934
    CrossrefPubMedGoogle Scholar
  • 52 Whitfield C L, Thompson G, Lamb A, Spencer v, Pfeifer M, Browning-Ferrando M. Detoxification of 1,024 alcoholic patients without psychoactive drugs.  JAMA. 1978;  239 1409-1410
    CrossrefPubMedGoogle Scholar
  • 53 WHO. Internationale Klassifikation psychischer Störungen ICD-10 Kapitel V (F) Forschungskriterien. Dilling H, Mombour W, Schmidt MH, Schulte-Warkwort E, eds Huber Bern; 1994
    Google Scholar
  • 54 Williams D, BcBride A J. The drug treatment of alcohol withdrawal symptoms: a systematic review.  Alcohol Alcohol. 1998;  33 103-115
    PubMedGoogle Scholar
  • 55 Wiseman E J, Henderson K L, Briggs M J. Individualized treatment for outpatients withdrawing from alcohol.  J Clin Psychiatry. 1998;  59 289-293
    CrossrefPubMedGoogle Scholar
  • 56 Wojnar M, Bizon Z, Wasilweski D. The role of somatic disorders and physical injury in the development and course of alcohol withdrawal delirium.  Alcohol Clin Exp Res. 1999;  23 209-213
    PubMedGoogle Scholar

Prof. Dr. M. Soyka

Psychiatric Hospital

University of Munich

Nussbaumstr. 7

80336 Munich

Germany

Phone: +49 89 5160 277

Fax: +49 89 5160 5617

Email: michael.soyka@med.uni-muenchen.de

      >